Legend Biotech (LEGN) Beginning Cash Balance (2020 - 2022)

Legend Biotech (LEGN) has 7 years of Beginning Cash Balance data on file, last reported at $278.9 million in Q4 2025.

• Quarterly Beginning Cash Balance fell 39.28% year-over-year to $278.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 billion (down 17.67% YoY) and the FY2025 annual result came in at $286.7 million, down 77.56% from the prior year.
• Beginning Cash Balance retreated to $278.9 million in Q4 2025, from $459.3 million in the prior quarter.
• In the past five years, Beginning Cash Balance ranged from a high of $963.5 million in Q4 2023 to a low of $278.9 million in Q4 2025.
• A 5-year average of $585.7 million and a median of $488.2 million in 2021 frame the typical range for Beginning Cash Balance.
• Annual changes were most pronounced in 2021 — Beginning Cash Balance surged 446.63% — and 2024, when it tumbled 52.33%.
• Tracing LEGN's Beginning Cash Balance over 5 years: stood at $338.3 million in 2021, then surged by 140.22% to $812.7 million in 2022, then rose by 18.55% to $963.5 million in 2023, then plunged by 52.33% to $459.3 million in 2024, then plunged by 39.28% to $278.9 million in 2025.
• The last three Beginning Cash Balance figures came in at $278.9 million (Q4 2025), $459.3 million (Q4 2024), and $963.5 million (Q4 2023), per Business Quant data.